U.S. markets open in 7 hours 28 minutes

Fusion Pharmaceuticals Inc. (FUSN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.86+0.16 (+1.84%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close8.70
Open8.57
Bid0.00 x 1000
Ask0.00 x 800
Day's Range8.57 - 8.86
52 Week Range8.09 - 19.00
Volume11,164
Avg. Volume39,931
Market Cap376.064M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est22.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study
      Benzinga

      Fusion Pharma Shares Move Higher After Trial Collab With Merck For IGF-1R-Expressing Cancer Study

      Fusion Pharmaceuticals Inc (NASDAQ: FUSN) has entered into a clinical trial collaboration with Merck & Co (NYSE: MRK) to evaluate Fusion's lead candidate, FPI-1434, in combination with Merck's Keytruda in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R). The planned Phase 1/2 combination trial will evaluate the safety, tolerability, and pharmacokinetics of FPI-1434 in combination with pembrolizumab. The study is expected to initiate approximately six to nine months after achieving the recommended Phase 2 dose in the ongoing Phase 1 study of FPI-1434 monotherapy. Under the terms of the agreement, Fusion will sponsor the study, and Merck will supply Keytruda. FPI-1434 is a radioimmunoconjugate designed to target and deliver alpha emitting medical isotopes to cancer cells expressing IGF-1R, a receptor that is overexpressed on many tumor types. Price Action: FUSN shares are up 2.16% at $8.98 on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaCardinal Health Stock Tumbles After Q3 Earnings Fall Short Of Expectations; Narrowed FY21 Adjusted EPS GuidanceTrevena's TRV027 To Be Tested In NIH-Funded COVID-19 Trial© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

    • Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R
      PR Newswire

      Fusion Pharmaceuticals Announces Clinical Collaboration with Merck to Evaluate Fusion's Targeted Alpha Therapy (TAT) in Combination with Merck's KEYTRUDA® (pembrolizumab) in Patients With Solid Tumors Expressing IGF-1R

      Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that it has entered into a clinical trial collaboration with a subsidiary of Merck (known as MSD outside the U.S. and Canada) to evaluate Fusion's lead candidate, [225Ac]-FPI-1434 (FPI-1434), in combination with Merck's anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with solid tumors expressing insulin-like growth factor 1 receptor (IGF-1R).

    • Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference
      CNW Group

      Fusion Pharmaceuticals to Present at the Bloom Burton & Co. Healthcare Investor Conference

      Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the Bloom Burton & Co. Healthcare Investor Conference on Tuesday, April 20, 2021 at 10:30am EDT. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.